Skip to main content
SpringerLink
Log in

Gastric Acid Secretions, Treatments, and Nutritional Consequences

  • Chapter
  • First Online:
Preventive Nutrition

Part of the book series: Nutrition and Health ((NH))

  • 2068 Accesses

Abstract

The objectives of this chapter are to provide an overview of the roles of gastric acid in health and disease, the use of acid-suppressive therapies to mitigate prevalent excess acid symptoms and/or diseases, and to review potential detrimental consequences related to their use. Particular emphasis is placed on the nutritional consequences of gastric acid imbalance as it is related to vitamin and mineral status. Finally, reduced gastric acid is also associated with disturbance in the natural bacterial balance throughout the gastrointestinal tract and the resulting gastrointestinal bacterial overgrowth is reviewed.

Key Points

• Gastric acid provides an important selective advantage today as when vertebrates evolved. With the eradication of one acid-related gastrointestinal (GI) disease there may be an increase in the incidence of another acid-related GI disease, demonstrating the importance of acid balance.

• Certain gastroesophageal diseases require chronic acid-suppressive therapy.

• Nutritional intervention at the initiation of acid-suppressive therapy could prevent adverse nutritional consequences.

• The effect of acid-suppressive therapy on both vitamin and mineral status is observed only after many years of therapy and recent clinical evidence is available to demonstrate such effects.

• Although the use of proton pump inhibitors (PPI) for the diagnosis and treatment of gastrointestinal disorders is effective, step-down strategies for acid-suppressive therapies should be developed and explored in support of updated indication.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 239.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134(7):1842–1860.

    Article  CAS  PubMed  Google Scholar 

  2. Pohl D, Fox M, Fried M, Goke B, Prinz C, Monnikes H, et al. Do we need gastric acid? Digestion 2008;77(3–4):184–197.

    Article  CAS  PubMed  Google Scholar 

  3. Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2007;23(6):595–601.

    Article  CAS  PubMed  Google Scholar 

  4. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol 2003;65:103–131.

    Article  CAS  PubMed  Google Scholar 

  5. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900–1920.

    Article  PubMed  Google Scholar 

  6. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135(4):1383–1391.

    Article  PubMed  Google Scholar 

  7. Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005;40(3):319–327.

    Article  CAS  PubMed  Google Scholar 

  8. Dent J, El Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54(5):710–717.

    Article  CAS  PubMed  Google Scholar 

  9. Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008;27(3):249–256.

    Article  CAS  PubMed  Google Scholar 

  10. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98(7):1487–1493.

    Article  PubMed  Google Scholar 

  11. Thoua NM, Khoo D, Kalantzis C, Emmanuel AV. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. Aliment Pharmacol Ther 2008;27(5):396–403.

    Article  CAS  PubMed  Google Scholar 

  12. Bruce mg, Maaroos HI. Epidemiology of Helicobacter pylori infection. Helicobacter 2008;13(Suppl. 1):1–6.

    Article  PubMed  Google Scholar 

  13. Kwok A, Lam T, Katelaris P, Leong RW. Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf 2008;7(3):271–281.

    Article  CAS  PubMed  Google Scholar 

  14. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008;40(8):619–626.

    Article  CAS  PubMed  Google Scholar 

  15. Permin H, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter infection. Helicobacter 2005;10(Suppl. 1):21–25.

    Article  CAS  PubMed  Google Scholar 

  16. Chmiela M, Michetti P. Inflammation, immunity, vaccines for Helicobacter infection. Helicobacter 2006;11(Suppl. 1):21–26.

    Article  CAS  PubMed  Google Scholar 

  17. McColl KE. How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers. Am J Gastroenterol 2009;104(1):190–193.

    Article  PubMed  Google Scholar 

  18. Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83(4):251–259.

    Article  CAS  PubMed  Google Scholar 

  19. Raghunath AS, O’Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005;22(Suppl. 1):55–63.

    Article  CAS  PubMed  Google Scholar 

  20. Raghunath AS, Hungin AP, Mason J, Jackson W. Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: a randomized controlled trial. Aliment Pharmacol Ther 2007;25(5):585–592.

    Article  CAS  PubMed  Google Scholar 

  21. Masaoka T, Suzuki H, Hibi T. Gastric epithelial cell modality and proton pump inhibitor. J Clin Biochem Nutr 2008;42(3):191–196.

    Article  CAS  PubMed  Google Scholar 

  22. Scheindlin S. A century of ulcer medicines. Mol Interv 2005;5(4):201–206.

    Article  PubMed  Google Scholar 

  23. Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci 2008;65(2):264–281.

    Article  CAS  PubMed  Google Scholar 

  24. Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001;15(3):487–495.

    Article  CAS  PubMed  Google Scholar 

  25. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004;126(25):7800–7811.

    CAS  Google Scholar 

  26. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104:S5–S9.

    Google Scholar 

  27. Tytgat GN, Heading RC, Muller-Lissner S, Kamm MA, Scholmerich J, Berstad A, et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 2003;18(3):291–301.

    Article  CAS  PubMed  Google Scholar 

  28. Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 2008;6(4):393–400.

    Article  PubMed  Google Scholar 

  29. Hampel H, Abraham NS, El Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143(3):199–211.

    PubMed  Google Scholar 

  30. Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 1999;34(4):337–340.

    Article  CAS  PubMed  Google Scholar 

  31. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey. Ann Epidemiol 1999;9(7):424–435.

    Article  CAS  PubMed  Google Scholar 

  32. Fisher BL, Pennathur A, Mutnick JL, Little AG. Obesity correlates with gastroesophageal reflux. Dig Dis Sci 1999;44(11):2290–2294.

    Article  CAS  PubMed  Google Scholar 

  33. Tran T, Lowry AM, El Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther 2007;25(2):143–153.

    CAS  PubMed  Google Scholar 

  34. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5(6):321–331.

    Article  CAS  PubMed  Google Scholar 

  35. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104(1):21–25.

    Article  CAS  PubMed  Google Scholar 

  36. Vakil N. H. pylori treatment: new wine in old bottles? Am J Gastroenterol 2009;104(1):26–30.

    Article  CAS  PubMed  Google Scholar 

  37. Vakil N. Helicobacter pylori treatment: is sequential or quadruple therapy the answer? Rev Gastroenterol Disord 2008;8(2):77–82.

    PubMed  Google Scholar 

  38. Niv Y. H pylori recurrence after successful eradication. World J Gastroenterol 2008;14(10):1477–1478.

    Article  PubMed  Google Scholar 

  39. Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134(4):937–944.

    Article  CAS  PubMed  Google Scholar 

  40. Konturek PC, Kania J, Hahn EG, Konturek JW. Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase. J Physiol Pharmacol 2006;57(Suppl. 5):125–136.

    PubMed  Google Scholar 

  41. Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 2007;23(8):1859–1866.

    Article  CAS  PubMed  Google Scholar 

  42. Physician’s Desk Reference: PDR—Aciphex Tablets (Eisai). PDR Electronic Library. 2008. 6-18-2008.

    Google Scholar 

  43. Physician’s Desk Reference: PDR—Prevacid Delayed-Release Capsules (TAP). PDR Electronic Library. 2008. 6-18-2008.

    Google Scholar 

  44. Physician’s Desk Reference: PDR—Nexium Delayed-Release Capsules (AstraZeneca LP). PDR Electronic Library. 2008. 6-18-2008.

    Google Scholar 

  45. Physician’s Desk Reference: PDR—Zegerid Powder for Oral Solution (Santarus). PDR Electronic Library. 2008. 6-18-2008.

    Google Scholar 

  46. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51(3):256–260.

    Article  CAS  PubMed  Google Scholar 

  47. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157(1):148–5.

    PubMed  Google Scholar 

  48. Green R. Is it time for vitamin B-12 fortification? What are the questions? Am J Clin Nutr 2009;89(2):712S–716S.

    Article  CAS  PubMed  Google Scholar 

  49. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc 2008;9(3):162–167.

    Article  CAS  PubMed  Google Scholar 

  50. Lechner K, Fodinger M, Grisold W, Puspok A, Sillaber C. Vitamin B12 deficiency. New data on an old theme. Wien Klin Wochenschr 2005;117(17):579–591.

    Article  CAS  PubMed  Google Scholar 

  51. Force RW, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM. Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003;37(4):490–493.

    Article  CAS  PubMed  Google Scholar 

  52. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull 2008;29(2 Suppl.):S20–S34.

    PubMed  Google Scholar 

  53. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994;120(3):211–215.

    CAS  PubMed  Google Scholar 

  54. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27(11):1110–1121.

    Article  CAS  PubMed  Google Scholar 

  55. Liu C, Russell RM. Nutrition and gastric cancer risk: an update. Nutr Rev 2008;66(5):237–249.

    Article  PubMed  Google Scholar 

  56. Fountoulakis A, Martin IG, White KL, Dixon MF, Cade JE, Sue-Ling HM, et al. Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus. Dig Dis Sci 2004;49(6):914–919.

    Article  CAS  PubMed  Google Scholar 

  57. Pietraforte D, Castelli M, Metere A, Scorza G, Samoggia P, Menditto A, et al. Salivary uric acid at the acidic pH of the stomach is the principal defense against nitrite-derived reactive species: sparing effects of chlorogenic acid and serum albumin. Free Radic Biol Med 2006;41(12):1753–1763.

    Article  CAS  PubMed  Google Scholar 

  58. Henry EB, Carswell A, Wirz A, Fyffe V, McColl KE. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther 2005;22(6):539–545.

    Article  CAS  PubMed  Google Scholar 

  59. Mowat C, Carswell A, Wirz A, McColl KE. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology 1999;116(4):813–822.

    Article  CAS  PubMed  Google Scholar 

  60. Mowat C, Williams C, Gillen D, Hossack M, Gilmour D, Carswell A, et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 2000;119(2):339–347.

    Article  CAS  PubMed  Google Scholar 

  61. Heaney RP. Bone as the calcium nutrient reserve. In: Weaver CM, Heaney RP, eds. Calcium in Human Health. Totowa, NJ: Humana Press Inc., 2006:7–12.

    Chapter  Google Scholar 

  62. Weaver CM, Heaney RP. Introduction. In: Weaver CM, Heaney RP, eds. Calcium in Human Health. Totowa, NJ: Humana Press Inc., 2006:1–3.

    Chapter  Google Scholar 

  63. Awumey EM, Bukoski RD. Cellular functions and fluxes of calcium. In: Weaver CM, Heaney RP, eds. Calcium in Human Health. Totowa, NJ: Humana Press Inc., 2006:13–35.

    Chapter  Google Scholar 

  64. Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev 2005;85(1):373–422.

    Article  CAS  PubMed  Google Scholar 

  65. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008;66(2):103–108.

    Article  PubMed  Google Scholar 

  66. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa AC, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984;73(3):640–647.

    Article  CAS  PubMed  Google Scholar 

  67. Heaney RP, Recker RR, Weaver CM. Absorbability of calcium sources: the limited role of solubility. Calcif Tissue Int 1990;46(5):300–304.

    Article  CAS  PubMed  Google Scholar 

  68. Heaney RP, Dowell SD, Bierman J, Hale CA, Bendich A. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 2001;20(3):239–246.

    CAS  PubMed  Google Scholar 

  69. Simonian HP, Vo L, Doma S, Fisher RS, Parkman HP. Regional postprandial differences in pH within the stomach and gastroesophageal junction. Dig Dis Sci 2005;50(12):2276–2285.

    Article  PubMed  Google Scholar 

  70. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985;313(2):70–73.

    Article  CAS  PubMed  Google Scholar 

  71. Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995;14(4):364–368.

    CAS  PubMed  Google Scholar 

  72. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005;118(7):778–781.

    Article  PubMed  CAS  Google Scholar 

  73. Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995;10(8):1376–1380.

    CAS  PubMed  Google Scholar 

  74. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947–2953.

    Article  CAS  PubMed  Google Scholar 

  75. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79(2):76–83.

    Article  CAS  PubMed  Google Scholar 

  76. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179(4):319–326.

    PubMed  Google Scholar 

  77. Grisso JA, Kelsey JL, O'Brien LA, Miles CG, Sidney S, Maislin G, et al. Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 1997;145(9):786–793.

    CAS  PubMed  Google Scholar 

  78. Roux KJ, Crisp ML, Liu Q, Kim D, Kozlov S, Stewart CL, et al. Nesprin 4 is an outer nuclear membrane protein that can induce kinesin-mediated cell polarization. Proc Natl Acad Sci U S A 2009.

    Google Scholar 

  79. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ 2008;179(4):306–307.

    PubMed  Google Scholar 

  80. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007;370(9586):511–520.

    Article  CAS  PubMed  Google Scholar 

  81. Brody T. Inorganic nutrients. Nutritional Biochemistry. London: Academic Press, 1999:693–878.

    Google Scholar 

  82. Hallberg L. Perspectives on nutritional iron deficiency. Annu Rev Nutr 2001;21:1–21.

    Article  CAS  PubMed  Google Scholar 

  83. Hurrell RF, Reddy MB, Juillerat M, Cook JD. Meat protein fractions enhance nonheme iron absorption in humans. J Nutr 2006;136(11):2808–2812.

    CAS  PubMed  Google Scholar 

  84. Cook JD, Brown GM, Valberg LS. The effect of achylia gastrica on iron absorption. J Clin Invest 1964;43:1185–1191.

    Article  CAS  PubMed  Google Scholar 

  85. Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology 1981;81(6):1068–1071.

    CAS  PubMed  Google Scholar 

  86. Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med 1978;92(1):108–116.

    CAS  PubMed  Google Scholar 

  87. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007;56(9):1291–1295.

    Article  CAS  PubMed  Google Scholar 

  88. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987;28(1):96–107.

    Article  CAS  PubMed  Google Scholar 

  89. Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JI, Robins-Browne RM, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun 2008;76(2):639–645.

    Article  CAS  PubMed  Google Scholar 

  90. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167(9):950–955.

    Article  CAS  PubMed  Google Scholar 

  91. Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006;117(5):e817-e820.

    Article  PubMed  Google Scholar 

  92. Al Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005;6(2):105–108.

    Article  PubMed  Google Scholar 

  93. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54(3):243–245.

    Article  CAS  PubMed  Google Scholar 

  94. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39(1):54–59.

    Article  CAS  PubMed  Google Scholar 

  95. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104:S10–S16.

    Google Scholar 

  96. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171(1):33–38.

    PubMed  Google Scholar 

  97. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294(23):2989–2995.

    Article  CAS  PubMed  Google Scholar 

  98. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 2003;17(12):1503–1506.

    Article  CAS  PubMed  Google Scholar 

  99. Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006;85(6):295–330.

    Article  CAS  Google Scholar 

  100. Elitsur Y, Lawrence Z. Non-Helicobacter pylori related duodenal ulcer disease in children. Helicobacter 2001;6(3):239–243.

    Article  CAS  PubMed  Google Scholar 

  101. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998;93(9):1409–1415.

    CAS  PubMed  Google Scholar 

  102. Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Vieth M, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006;163(11):1025–1034.

    Article  PubMed  Google Scholar 

  103. Jang HJ, Choi MH, Shin WG, Kim KH, Chung YW, Kim KO, et al. Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study. Dig Dis Sci 2008;53(6):1527–1531.

    Article  PubMed  Google Scholar 

  104. Gisbert JP, Blanco M, Mateos JM, Fernandez-Salazar L, Fernandez-Bermejo M, Cantero J, et al. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999;44(11):2295–2302.

    Article  CAS  PubMed  Google Scholar 

  105. De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 2008;93(2):363–371.

    Article  PubMed  CAS  Google Scholar 

  106. Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers Prev 2006;15(6):1083–1094.

    Article  PubMed  Google Scholar 

  107. Kuipers EJ. Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes? Basic Clin Pharmacol Toxicol 2006;99(3):187–194.

    Article  CAS  PubMed  Google Scholar 

  108. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 2002;36(5):812–816.

    Article  PubMed  Google Scholar 

  109. AstraZeneca. Prilosec Package Insert (omeprazole and omeprazole magnesium). Package Insert. 2009.

    Google Scholar 

  110. Physician’s Desk Reference: PDR—Protonix Tablets (Wyeth). PDR Electronic Library. 2008. 6-18-2008.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GSK Consumer Healthcare, 07054, Parsippany, NJ, USA

    Ronit Zilberboim PHD (Principle Clinical Scientist, Medical Affairs) & Adrianne Bendich PHD, FACN

Authors
  1. Ronit Zilberboim PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrianne Bendich PHD, FACN
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. New Products Research, GlaxoSmithKline Consumer Healthcare, Littleton Road 1500 , Parsippany, 07054, U.S.A.

    Adrianne Bendich

  2. Inst. Human Nutrition, Columbia University, West 168th St. 630 , New York, 10032, U.S.A.

    Richard J. Deckelbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Zilberboim, R., Bendich, A. (2010). Gastric Acid Secretions, Treatments, and Nutritional Consequences. In: Bendich, A., Deckelbaum, R. (eds) Preventive Nutrition. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60327-542-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-542-2_20

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-541-5

  • Online ISBN: 978-1-60327-542-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation